More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review.
about
Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remissionLong-responders to anti-HER2 therapies: A case report and review of the literature.Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
P2860
More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
More than 9 years of continuou ...... report and literature review.
@ast
More than 9 years of continuou ...... report and literature review.
@en
More than 9 years of continuou ...... report and literature review.
@nl
type
label
More than 9 years of continuou ...... report and literature review.
@ast
More than 9 years of continuou ...... report and literature review.
@en
More than 9 years of continuou ...... report and literature review.
@nl
prefLabel
More than 9 years of continuou ...... report and literature review.
@ast
More than 9 years of continuou ...... report and literature review.
@en
More than 9 years of continuou ...... report and literature review.
@nl
P2093
P2860
P356
P1476
More than 9 years of continuou ...... report and literature review.
@en
P2093
Adriana Badulescu
Carmen Florina Popescu
Cristina Florescu
Florin Badulescu
P2860
P304
P356
10.2147/OTT.S69343
P407
P577
2014-10-17T00:00:00Z